-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
PDB drug comprehensive database data has been updated to
PDB drug comprehensive database data has been updated to The aftermath of the new crown epidemic has not yet dissipated, and sporadic domestic epidemics have rebounded
.
On the basis of ensuring the prevention and control of the epidemic, in the first half of 2021, the market sales of sample hospitals in China's key cities have increased significantly, with a year-on-year increase of approximately 17.
Figure 1 2012-2021 Q2 analysis of sales growth of sample hospitals in key cities in my country
We analyze the various treatment markets according to the ATC classification.
In the first half of 2021, anti-tumor drugs and immunomodulatory inhibitors, total digestive tract and metabolic drugs, and systemic anti-infective drugs will cost 25.
3 billion yuan, 15.
8 billion yuan, and 15.
1 billion yuan respectively.
Sales rank among the top three.
Compared with the same period in 2020, the sales of anti-tumor drugs and immunosuppressants have increased significantly, exceeding 30%! Other treatment categories have basically achieved rapid growth
.
According to current trends, the second half of this year may usher in an "outbreak" of performance in various treatment categories
Figure 2 Sales analysis of various treatment categories in 2021 Q1-Q2 and 2020
In the first half of 2021, there are 83 products with sales exceeding 250 million yuan, 24 products with sales exceeding 500 million yuan, and only 6 products with sales exceeding 1 billion yuan
.
We compiled the top 20 drugs in sales in the first half of 2021 and compared them with the sales rankings in 2020
It can be found that human albumin is still firmly in the "throne" and its position is unshakable.
It leads the list with a sales of 2.
38 billion yuan, which is 900 million yuan higher than the second place sodium chloride! The third place is Bevar.
Rizumab has a very eye-catching performance this year.
It beat Dezocine with a sales of 1.
18 billion yuan and became the third runner-up with a slight advantage
.
The traditional "three brothers" paclitaxel did not perform well in the first half of this year.
Figure 3 Sales of TOP20 products in Q1-Q2 2021
Selecting the top 10 companies in revenue in the first half of this year, it is obvious that the growth of leading foreign companies is facing difficulties.
AstraZeneca, Pfizer, Roche, Bayer, and Novartis all have negative growth, and the pressure has increased sharply
.
Although AstraZeneca can barely maintain the first place, Hengrui has already beaten Roche and Pfizer consecutively, rushing to the second place with 3.
Figure 4 Sales of TOP10 companies in Q1-Q2 2021
With the expansion of centralized procurement, the pattern of my country's pharmaceutical industry is constantly changing, and the general trend of domestic substitution has been irreversible.
